2011
Impact of marital status and race on outcomes of patients enrolled in Radiation Therapy Oncology Group prostate cancer trials
Du KL, Bae K, Movsas B, Yan Y, Bryan C, Bruner DW. Impact of marital status and race on outcomes of patients enrolled in Radiation Therapy Oncology Group prostate cancer trials. Supportive Care In Cancer 2011, 20: 1317-1325. PMID: 21720747, DOI: 10.1007/s00520-011-1219-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicFollow-Up StudiesHumansKaplan-Meier EstimateLogistic ModelsMaleMarital StatusMiddle AgedPrognosisProportional Hazards ModelsProstatic NeoplasmsRacial GroupsRandomized Controlled Trials as TopicSurvival RateTime FactorsTreatment FailureTreatment OutcomeConceptsPathologic prognostic factorsPrognostic factorsProportional hazards modelOverall survivalMedian timeSociodemographic factorsWhite patientsCancer outcomesPrognostic indicatorProstate cancerMarital statusImproved prostate cancer outcomesHigh-risk cancer patientsGray proportional hazards modelsCommon visceral cancerOutcomes of patientsBiochemical failure rateCumulative incidence methodSignificant prognostic factorsCancer-related outcomesKaplan-Meier methodProstate cancer outcomesGroup of patientsNon-white patientsProstate cancer risk
2006
Preliminary results of interstitial motexafin lutetium‐mediated PDT for prostate cancer
Du KL, Mick R, Busch TM, Zhu TC, Finlay JC, Yu G, Yodh AG, Malkowicz SB, Smith D, Whittington R, Stripp D, Hahn SM. Preliminary results of interstitial motexafin lutetium‐mediated PDT for prostate cancer. Lasers In Surgery And Medicine 2006, 38: 427-434. PMID: 16788929, DOI: 10.1002/lsm.20341.Peer-Reviewed Original ResearchConceptsInterstitial photodynamic therapyProstate adenocarcinomaProstate cancerPhotodynamic therapyRecurrent prostate adenocarcinomaSolid organ diseaseSubsequent tissue necrosisOrgan diseaseDrug levelsPreclinical studiesClinical experienceSTUDY DESIGN/MATERIALSTissue necrosisDose distributionDESIGN/MATERIALSPhase IAdenocarcinomaHuman subjectsProstateCancerTreatmentUniversity of PennsylvaniaDose variationComprehensive treatmentPatients